The challenge
Charcot–Marie–Tooth disease type 1A (CMT1A) is an inherited peripheral neuropathy associated with increased PMP22 gene dosage. It can progressively affect sensation, strength and mobility.
Our lead investigational gene therapy program aims to reduce excess PMP22 expression through localized perineural AAV delivery.

Charcot–Marie–Tooth disease type 1A (CMT1A) is an inherited peripheral neuropathy associated with increased PMP22 gene dosage. It can progressively affect sensation, strength and mobility.
NVO-101 uses an AAV9-based vector designed to express an RNA-interference payload targeting PMP22 in Schwann cells. Perineural administration is intended to reach the targeted nerve while limiting systemic exposure.
Preclinical research has supported the rationale for this approach. The program is being advanced toward clinical evaluation; safety and efficacy in people have not been established.
Investigational research program. Preclinical observations do not demonstrate clinical safety or efficacy.
We welcome conversations with scientific, clinical and strategic partners.